2017 West Coast Microbiome Forum-2017-09-11

Event Information
Event Name: 
2017 West Coast Microbiome Forum
Event Date: 
09/11/2017 - 10:00am
Event Location: 
Quadrus Conference Center, Menlo Park, CA 94025
Event Details
Event Type: 
Panel Discussions
Event Details: 

JLABS, Monday-Tuesday, Sept. 11-12, 2017

Join the Janssen Human Microbiome Institute, JLABS @ SSF, Stanford Medicine, and Seventure for the 2017 West Coast Microbiome Forum, a 2-day event exploring key aspects of microbiome research. **Note - There is separate registration for each day.

September 11: Bioinformatics for the Microbiome, hosted by Stanford Medicine. Details/Register with Stanford here (Link will redirect you to a non-J&J Innovation website)
September 12: Bugs, Drugs & Beyond: Translational Approaches to the Mircrobiome, hosted by JHMI and JLABS.

Bugs, Drugs & Beyond: Translational Approaches will explore the ways in which innovators from San Francisco and beyond are harnessing the human microbiome and advancing novel therapeutics, diagnostics and other health products. During this event, we'll hear from entrepreneurs, academics, investors, and biotech and pharma companies about a variety of product development approaches and the organizations pursuing them.
10:00am | Registration
10:15am | The Microbiome: A New Paradigm for Health Solutions
10:30am | Insights from the Front Lines of Microbiome Innovation
11:00am | QuickFire Challenge, Part I
12:00pm | Lunch and Gallery Walk
1:15pm | Panel Discussion: From Validation to Regulation: Breaking Down Barriers to Microbiome Progress
2:15pm | QuickFire Challenge, Part II
3:15pm | Networking Reception and QuickFire Challenge Winner Announced
4:30pm | Program Close

Interactive sessions will highlight:
Challenges in advancing to market, from IP protection to commercialization
Potential solutions and pathways currently being pursued across the field
Opportunities for collaboration
The Bugs, Drugs & Beyond QuickFire Challenge:
Are you a game-changing early-stage microbiome company? The Bugs, Drugs & Beyond QuickFire Challenge is officially open! We encourage innovators with promising ideas or research with the potential to impact patients to apply now. The winner will be awarded a customized package of support from the JHMI and JLABS, and will be announced at the event of the event on September 12. Applications for the Bugs, Drugs, & Beyond QuickFire Challenge will remain open until July 14, 2017. Apply online today!

Miguel Barbosa | Chief Scientific Officer -Microbiome, Assembly Biosciences ;
Colleen Cutcliffe | CEO, Whole Biome Inc.;
Dirk Gevers | Global Head, Janssen Human Microbiome Institute, Janssen R&D Denise Kelly | Investment Advisor, Seventure; Justin Sonnenburg | Principal Investigator, Stanford University
[Moderator] Stephanie Roberston | Sr Director of Consumer Science Innovation, Johnson & Johnson Innovation
Location: Quadrus Conference Center, Menlo Park, CA 94025
$40 | General Public
$20 | Student/Academic
$45 | At the door
Details and registration at https://www.eventbrite.com/e/bugs-drugs-beyond-translational-approaches-...

Speakers' Biographies:
Miguel Barbosa | Chief Scientific Officer -Microbiome, Assembly Biosciences
Dr. Barbosa has more than two decades of experience leading drug discovery and development programs at major pharmaceutical and biotechnology companies. Until 2015, Dr. Barbosa was Global Head and Vice President of Immunology Research and External Innovation at Janssen Research & Development, where he oversaw immunology R&D and new program initiatives, including establishing the foundation for, and then leading, Johnson & Johnson's new microbiome enterprise. Earlier in his career, Dr. Barbosa held positions of increasing responsibility managing new drug R&D programs at prominent biopharmaceutical firms, including Centocor, Signal Pharmaceuticals, TRL USA, Chugai Biopharma and Mirna Therapeutics. Dr. Barbosa received a BS degree from the University of California, Davis and a PhD from the University of California, Los Angeles. He completed a post-doctoral fellowship at the National Cancer Institute..

Joseph Petrosino Colleen Cutcliffe | CEO and Co-founder, Whole Biome, Inc.
Colleen Cutcliffe is the CEO and Co-Founder of Whole Biome Inc. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Whole Biome, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College..
^ Back to Speakers' list ^

Stephanie Robertson Dirk Gevers | Global Head, Janssen Human Microbiome Institute, Janssen R&D
Dirk Gevers, Ph.D., is Global Head of the Janssen Human Microbiome Institute (JHMI), where he leads efforts to expand scientific understanding and capabilities in this emerging area of science. Previously, Dirk was Senior Group Leader of Microbial Systems and Communities at the Broad Institute of MIT and Harvard, serving as a scientific liaison among various organizational components, including the institute's data generation platforms and both clinical and analytical collaborators on microbiome-related projects. Dirk's research included the characterization of the microbial imbalance associated with diseases such as Crohn's disease, type 1 diabetes and colorectal cancer. He was also involved with the National Institutes of Health Human Microbiome Project, holding a leading role in the Data Analysis Working Group. Dirk received his Ph.D. in biochemistry from Ghent University (UGent), Belgium, and completed postdoctoral training at UGent and the Massachusetts Institute of Technology in bioinformatics, comparative and evolutionary genome analysis and microbial ecology.
^ Back to Speakers' list ^

Justin Sonnenburg Denise Kelly | Investment Advisor, Seventure
Denise joined Seventure in September 2015 as an investment Advisor to the Life Sciences Team for microbiome field. Her focus is in Human Microbiome Research and her time is dedicated to coverage of scientific and academic community on behalf of Seventure, and to prospect new investment opportunities in the specific field of microbiome. Denise is currently based in Aberdeen, Scotland. Prior to joining Seventure, Denise was Head of her Research team at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies.

Denise Kelly Justin Sonnenburg | Principal Investigator, Stanford University
Justin Sonnenburg conducted his Ph.D. in Biomedical Sciences at the University of California, San Diego. His graduate studies in the laboratory of Ajit Varki focused on the biological roles of glycosylation, performing comparative studies on sialic acids and their receptors in humans and great apes, to shed light on the molecular evolutionary history of humans. In 2003, Justin moved to Washington University in Saint Louis, Missouri to join the laboratory of Jeffrey Gordon, where he applied his background in glycobiology to study host-microbial interactions within the gastrointestinal tract. During his post-doc, Justin investigated model microbial communities living within the gut of gnotobiotic mice to define the basic principles that govern interactions within the microbiota and between the microbiota and the host. In 2008, Justin moved back to California and is currently Assistant Professor in the Department of Microbiology and Immunology at the Stanford University School of Medicine. In 2009 Justin was the recipient of an NIH Director's New Innovator Award. In 2011 he received the Burroughs Wellcome Fund Investigators in Pathogenesis of Infectious Disease Award. He and Erica Sonnenburg, PhD, are the authors of the forthcoming book The Good Gut: Taking Control of Your Weight, Your Mood, and Your Long Term Health.

The Sonnenburg lab is currently focused on understanding basic principles that govern interactions within the intestinal microbiota and between the microbiota and the host. To pursue these aims, his lab colonizes germ-free (gnotobiotic) mice with simplified, model microbial communities, applies systems approaches (e.g. functional genomics), and uses genetic tools for the host and microbes to gain mechanistic insight into emergent properties of the host-microbial super-organism.
^ Back to Speakers' list ^

Migeul Barbosa Stephanie Roberston| Sr Director of Consumer Science Innovation, Johnson & Johnson Innovation
Stephanie is part of the New Ventures Team at J&J Innovation. As part of her role at J&J Innovation, she works closely with the Janssen Human Microbiome Institute and with J&J Consumer Emerging Sciences to create collaborations with academic experts and biotech companies with a goal of accelerating the translation of microbiome research into breakthrough solutions that promote health. Previously Stephanie was at the University of California, San Francisco UCSF where she helped to establish and grow translational efforts on campus including her role as Program Director for the Sandler Center for Drug Discovery, and for the Grand Multiple Myeloma Translational Initiative. She later took on the role of Director, Strategic Alliances where she led business development and alliance management activities for the campus. Prior to joining UCSF, Stephanie worked for over a decade at Exelixis, Inc, where she held diverse leadership roles including leading a computational biology team and acting as scientific project leader for numerous drug discovery programs in cancer, cardiovascular disease and metabolism as well as managing early oncology clinical programs and alliances for several programmatic collaborations with large pharma.

Stephanie earned an undergraduate degree in chemistry (Honors) at the University of Michigan, Ann Arbor, and a Ph.D. in chemistry at the University of California, Berkeley.